Clinical Trial Update: CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating cardio-protection with dapagliflozin in breast cancer patients treated with anthracyclines; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Heart Failure

Drugs mentioned

• Dapagliflozin (Farxiga) (dapagliflozin)

Snippet

Sponsor: 4th Military Clinical Hospital with Polyclinic, Poland | Conditions: Breast Cancer, Heart Failure | Phase 3 | Status: RECRUITING